Q2 2014 13F Holders as of 30 Jun 2014
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
20.8M
-
Number of holders
-
141
-
Total 13F shares, excl. options
-
114M
-
Shares change
-
-1.62M
-
Total reported value, excl. options
-
$1.46B
-
Value change
-
-$20.6M
-
Put/Call ratio
-
0.22
-
Number of buys
-
60
-
Number of sells
-
-74
-
Price
-
$12.82
Significant Holders of Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NKTR) as of Q2 2014
172 filings reported holding NKTR - Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q2 2014.
Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NKTR) has 141 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 114M shares
.
Largest 10 shareholders include OPPENHEIMER FUNDS INC (24.4M shares), PRIMECAP MANAGEMENT CO/CA/ (15.8M shares), VANGUARD GROUP INC (8.08M shares), FEDERATED INVESTORS INC /PA/ (5.91M shares), FIRST TRUST ADVISORS LP (5.26M shares), State Street Corp (4.68M shares), BlackRock Fund Advisors (4.48M shares), JPMORGAN CHASE & CO (4.39M shares), GRANAHAN INVESTMENT MANAGEMENT INC/MA (3.67M shares), and Bank of New York Mellon Corp (3.55M shares).
This table shows the top 141 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.